ANNOUNCEMENT 02 Jun 2021

The Indian state of Maharashtra has announced a financial grant for the production of an indigenous COVID-19 vaccine.

NUMBER OF INTERVENTIONS

1

  • 1 harmful
  • 0 neutral
  • 0 liberalising

SOURCE

Centre takes steps to accelerate domestic vaccine production
Haffkine Biopharma to produce 22.8 crore doses per annum of Covaxin under technology transfer arrangement with Bharat Biotech
https://pib.gov.in/PressReleseDetail.aspx?PRID=1723608

Inception date: 02 Jun 2021 | Removal date: open ended

Financial grant

On 2 June 2021, the Indian Ministry of Science and Technology specified in a press release that a grant of INR 94 crore (~USD 12.9 million) has been provided to Haffkine Biopharmaceutical Corporation Limited by the state of Maharashtra for the production of Covaxin. Covaxin is an indigenously developed COVID-19 vaccine in India.

Along with the state of Maharastra, the Indian government has also provided an INR 65 crore grant to Hakkfine under the Mission COVID Suraksha program (see related State Act).

Haffkine Biopharmaceutical Corporation Limited is a Maharashtra state public sector enterprise and is headquartered in Mumbai, Maharashtra.

* INR to USD as of 2 June 2021 - INR 72.96/USD

AFFECTED SECTORS

 

AFFECTED PRODUCTS